论文部分内容阅读
肺癌是发病率和死亡率增长最快,对人群健康和生命威胁最大的恶性肿瘤之一,受到广泛关注。表皮生长因子受体(EGFR)酪氨酸激酶与肿瘤细胞增殖、黏附、迁移和分化过程密切相关。研究表明,抑制EGFR酪氨酸激酶活性可以有效抑制肿瘤生长。近年来,开发出许多以EGFR为靶点的药物,在肿瘤治疗方面取得了很好的效果。本文综述了EGFR抑制剂近期的研究进展。
Lung cancer is one of the malignant tumors with the highest growth rate of morbidity and mortality and the most serious threat to human health and life. Epidermal growth factor receptor (EGFR) tyrosine kinase is closely related to the proliferation, adhesion, migration and differentiation of tumor cells. Studies have shown that inhibition of EGFR tyrosine kinase activity can effectively inhibit tumor growth. In recent years, many EGFR-targeted drugs have been developed that have achieved good results in oncology treatment. This review summarizes the recent progress of EGFR inhibitors.